Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 2
2005 2
2006 3
2007 1
2008 7
2009 15
2010 12
2011 49
2012 45
2013 35
2014 48
2015 82
2016 94
2017 94
2018 116
2019 104
2020 99
2021 122
2022 110
2023 87
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

1,029 results

Results by year

Filters applied: . Clear all
Page 1
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10. Lancet. 2016. PMID: 26874885 Free article. Clinical Trial.
Treatment-emergent adverse events occurred in 224 (99%) of 226 patients who received eribulin and 218 (97%) of 224 who received dacarbazine. Grade 3 or higher adverse events were more common in patients who received eribulin (152 [67%]) than in those who received da …
Treatment-emergent adverse events occurred in 224 (99%) of 226 patients who received eribulin and 218 (97%) of 224 who received dacar …
Eribulin.
Perry CM. Perry CM. Drugs. 2011 Jul 9;71(10):1321-31. doi: 10.2165/11207520-000000000-00000. Drugs. 2011. PMID: 21770478 Review.
Eribulin (eribulin mesylate) is a non-taxane microtubule dynamics inhibitor with tubulin-based antimitotic activity and chemotherapeutic effects. ...In in vitro studies, eribulin displayed antiproliferative activity against human breast cancer cell lines. ...
Eribulin (eribulin mesylate) is a non-taxane microtubule dynamics inhibitor with tubulin-based antimitotic activity and chemot …
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Cortes J, et al. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2. Lancet. 2011. PMID: 21376385 Clinical Trial.
FINDINGS: 762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC). Overall survival was significantly improved in women assigned to eribulin (median 13.1 months, 95% CI 11.8-14.3) compared with TPC (10.6 months, 9.3-12.5; hazard ratio 0.81, 95% …
FINDINGS: 762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC). Overall survival was significantly improved …
Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL. Setola E, et al. Expert Rev Anticancer Ther. 2017 Aug;17(8):717-723. doi: 10.1080/14737140.2017.1344098. Epub 2017 Jun 28. Expert Rev Anticancer Ther. 2017. PMID: 28621163 Review.
The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects. Expert commentary: Eribulin is highly effective in some STS populations and …
The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing antican …
Clinical and preclinical features of eribulin-related peripheral neuropathy.
Tarasiuk O, Cavaletti G, Meregalli C. Tarasiuk O, et al. Exp Neurol. 2022 Feb;348:113925. doi: 10.1016/j.expneurol.2021.113925. Epub 2021 Nov 18. Exp Neurol. 2022. PMID: 34801586 Review.
Current clinical evidence suggests that eribulin treatment, unlike some of the other MTAs, is associated with a relatively low incidence of severe peripheral neuropathy. This suggests that different MTAs possess unique mechanisms of neuropathologic induction. Animal models …
Current clinical evidence suggests that eribulin treatment, unlike some of the other MTAs, is associated with a relatively low incide …
Eribulin in Cancer Treatment.
Swami U, Shah U, Goel S. Swami U, et al. Mar Drugs. 2015 Aug 7;13(8):5016-58. doi: 10.3390/md13085016. Mar Drugs. 2015. PMID: 26262627 Free PMC article. Review.
Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a t …
Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthet …
Eribulin mesylate.
Jain S, Vahdat LT. Jain S, et al. Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. Clin Cancer Res. 2011. PMID: 21859830 Review.
Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U.S. ...Eribulin significantly increased overall survival (OS; median OS for the eribulin-treated group was 13.1 months versus 10.6 months for the gr …
Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U.S. ...Eribulin …
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Kaufman PA, et al. J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605862 Free PMC article. Clinical Trial.
PURPOSE: This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC). ...Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, …
PURPOSE: This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients …
Eribulin in non-small cell lung cancer: challenges and potential strategies.
Swami U, Shah U, Goel S. Swami U, et al. Expert Opin Investig Drugs. 2017 Apr;26(4):495-508. doi: 10.1080/13543784.2017.1292250. Epub 2017 Feb 22. Expert Opin Investig Drugs. 2017. PMID: 28161993 Review.
Eribulin is a non-taxane, macrocyclic, synthetic, ketone analog of halichondrin B with a microtubule inhibitory action specific toward plus ends. ...Expert opinion: Eribulin is a potent chemotherapeutic agent with acceptable and easily manageable toxicity profile. . …
Eribulin is a non-taxane, macrocyclic, synthetic, ketone analog of halichondrin B with a microtubule inhibitory action specific towar …
Multifarious targets beyond microtubules-role of eribulin in cancer therapy.
Seshadri P, Deb B, Kumar P. Seshadri P, et al. Front Biosci (Schol Ed). 2021 Dec 3;13(2):157-172. doi: 10.52586/S559. Front Biosci (Schol Ed). 2021. PMID: 34879468 Free article. Review.
Eribulin, a synthetic marine based drug has received extensive attention recently due to its promising anticancer activities against a wide variety of cancer types as evidenced by preclinical and clinical data. ...We have also highlighted approaches including combination t …
Eribulin, a synthetic marine based drug has received extensive attention recently due to its promising anticancer activities against …
1,029 results